China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal certificate from Indonesia’s LPPOM MUI for its recombinant novel coronavirus vaccine, which uses an adenovirus type 5 vector. This certification is a significant step for the company as it seeks to expand its vaccine’s reach within the Muslim community.
Convidecia Vaccine Gains Access to Muslim Markets
Convidecia, co-developed by the China Academy of Military Medical Sciences, is now poised to enter the Muslim world with this recognition. The halal certification will likely facilitate the vaccine’s acceptance and use among Muslim populations, who observe dietary and lifestyle guidelines in accordance with Islamic law.
Implications of Halal Certification for CanSino Biologics
The receipt of the halal certificate not only broadens the potential market for CanSino Biologics’ Convidecia vaccine but also underscores the company’s commitment to meeting the needs of diverse global communities. This development is expected to enhance the vaccine’s appeal and accessibility in Indonesia and other Muslim-majority countries, contributing to the global effort to combat the COVID-19 pandemic.-Fineline Info & Tech
